Customize your JAMA Network experience by selecting one or more topics from the list below.
Variation in the prevalence of risk factors can account for differences in health outcomes. The US Burden of Disease Collaborators analyzed published studies and data sources by age, sex, geography, and year and found that differences in health outcomes were attributable to substance use disorders, high body mass index, diet, and high fasting plasma glucose. In an Editorial, Koh and Parekh suggest that greater investment in public health and social programs could yield healthier behaviors and more supportive environments.
Author Audio Interview and CME
Stepwise escalation in therapy is recommended for patients with persistent asthma despite daily use of inhaled corticosteroids. Sobieraj and colleagues conducted a systematic review and meta-analysis of 15 randomized clinical trials in 7122 patients with uncontrolled, persistent asthma and concluded that adding a long-acting muscarinic antagonist to inhaled corticosteroids was associated with a lower risk of asthma exacerbations. In an Editorial, Krishnan and Au call for an update to current guidelines on pharmacotherapies for persistent asthma.
Editorial and Related Article
Single maintenance and reliever therapy is the use of a combination inhaled corticosteroid and long-acting β-agonist as both controller and quick relief therapy for patients with asthma. In a systematic review and meta-analysis of 16 randomized clinical trials in 22 748 patients with persistent asthma, Sobieraj and colleagues concluded that single maintenance and reliever therapy, compared with other controller and relief therapies, was associated with a lower risk of asthma exacerbations.
Sequencing of tumor DNA can identify tumor-associated somatic mutations to predict treatment response, guide therapy selection, and serve as molecular markers for disease monitoring. In this JAMA Insights article, Spencer and Ley compare the utility and value of exome and gene panel sequencing.
This JAMA Clinical Challenge by Haley and colleagues presents a 58-year-old man with a blistering intertriginous rash that worsened in the summer months. What would you do next?
Benralizumab is a humanized monoclonal antibody that binds to the interleukin-5 receptor to decrease eosinophilic airway inflammation. This Medical Letter on Drugs and Therapeutics discusses the efficacy and safety of benralizumab for patients with poorly controlled severe asthma and elevated eosinophil levels.
Highlights. JAMA. 2018;319(14):1415–1417. doi:10.1001/jama.2017.12317
Create a personal account or sign in to: